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osting by EAbstract Canaloplasty is a method of lowering intraocular pressure (IOP) by which a ﬂexible, bea-
con-tipped microcatheter equipped with an ophthalmic viscosurgical device (OVD) delivery system
is used to catheterize and introduce a suture into Schlemm’s canal. Ligation of this suture provides
tension on the canal and facilitates aqueous outﬂow. Canaloplasty is designed to be a blebless pro-
cedure that requires no antiﬁbrotic agents and has been shown to safely and effectively lower IOP in
patients with open-angle glaucoma (OAG) with minimal complications. Most importantly, no bleb-
related adverse events are associated with this procedure. When contemplating surgical manage-
ment of OAG, canaloplasty may be considered.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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The mainstay of glaucoma treatment is lowering of IOP. The
classic treatment algorithm consists of initial medical manage-
ment followed by incisional glaucoma surgery if necessary with
laser therapy sometimes utilized as bridge therapy. Many vari-
ations of this paradigm exist. The most popular glaucoma sur-
gery utilized is the trabeculectomy with the use of Mitomycin
C, which redirects aqueous from the anterior chamber to a
subconjunctival bleb. This procedure, while very effective at
lowering IOP, is associated with multiple risks and complica-
tions. Intraoperative and postoperative risks include hypot-
ony, hyphema, choroidal detachment and suprachoroidal
hemorrhage. The blebs may be associated with bleb leak, bleb
encapsulation, bleb dysesthesia, blebitis and bleb-associated
endophthalmitis (Greenﬁeld et al., 1996; Prasad and Latina,
2007; Radhakrishnan et al., 2009; Azuara-Blanco and Katz,
1998; Borisuth et al., 1999).
Such complications have encouraged many glaucoma spe-
cialists to seek out a less invasive IOP-lowering surgery. Re-
cently circumferential viscodilation and tensioning of
Schlemm’s canal using a ﬂexible microcatheter (canaloplasty)
in combination with deep sclerectomy has raised interest for
the treatment of OAG in adults. The purpose of this review
is to present an update on the current status of this procedure.
2. Surgical procedure
Canaloplasty is a surgery in which Schlemm’s canal is isolated
and catherized using a microcatheter equipped with an optical
illuminating beacon at its tip and an OVD delivery system.
This microcatheter is used to introduce a suture into
Schlemm’s canal, which provides enough circumferential ten-
sion to distend the canal with the purpose of increasing out-
ﬂow and decreasing IOP.
A retrobulbar block achieves anesthesia and akinesia pre-
operatively. The eye is inferoducted after placement of a clearFigure 1 Limbal peritomy.corneal traction suture near the limbus. This may be accom-
plished with a traditional single-pass or double-pass technique.
During the latter, 6-0 or 7-0 polyglactin (Vicryl, Ethicon, Swit-
zerland) is passed perpendicular to the limbus in an anterior-
to-posterior direction exiting near the limbus with the ﬁrst
pass. A second pass occurs approximately 2–3 clock-hours
away from the initial pass and enters near and perpendicular
to the limbus traversing the cornea in a posterior-to-anteriorFigure 3 Deep scleral ﬂap.
Figure 4 Anterior chamber paracentesis.
Figure 5 Creating descemet’s window.
Figure 6 Advancing the microcatheter through Schlemm’s
canal.
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to the limbus. The exposed Vicryl parallel to the limbus can be
used to secure the superﬁcial scleral ﬂap during deep scleral
ﬂap creation and canal unrooﬁng.
Canaloplasty begins with a 2–3 clock-hour limbal peritomy
followed by exposure of bare sclera accomplished via meticu-
lous dissection of conjunctiva and tenon’s capsule with wetﬁeld
cautery used for hemostasis (Fig. 1). Unlike a traditional tra-
beculectomy procedure, no antiﬁbrotics are necessary. The
location of canal entrance may be tailored to ﬁt individual
needs. Some surgeons favor a superonasal approach thus spar-
ing the superior and superotemporal conjunctiva should fu-
ture, more invasive incisional glaucoma surgeries be
necessary. Still other surgeons prefer a more conservative infe-
rior approach completely sparing the superior conjunctiva.
Schlemm’s canal can be isolated after dissection of two
scleral ﬂaps. The ﬁrst, superﬁcial ﬂap should be approximately
one-third to one-half scleral thickness, and dissection of this
ﬂap should be initiated well into clear cornea by approximately
one millimeter to allow ample area for creation of the desce-
metic window (Fig. 2). A 5 mm · 5 mm parabolic or triangular
ﬂaps are common techniques employed. This superﬁcial scleral
ﬂap may be retracted with the double-pass traction suture de-
scribed above. Next, a deep scleral ﬂap with a parameter one-
half to one millimeter smaller than the superﬁcial ﬂap is fash-
ioned within the base of the previous ﬂap with a dissection
plane immediately superﬁcial to the choroid (Fig. 3). Choroi-dal exposure may occur. Anterior dissection of the deep scleral
ﬂap unroofs Schlemm’s canal. Cross striations of the scleral
spur serve as anatomic landmarks during creation of the deep
ﬂap, as Schlemm’s canal is immediately anterior. Locating this
landmark ensures correct depth and plane of dissection.
The eye must now be decompressed in order to decrease the
risk of anterior chamber perforation. Paracentesis wound for-
mation with subsequent aqueous release lowers the intraocular
pressure to mid-to-high single digits, which is optimal for iso-
lating Schlemm’s canal and creating a trabeculo-descemetic
window (TDW) (Fig. 4). After releasing pressure in the ante-
rior chamber the dissection of the deep ﬂap anteriorly isolates
Schlemm’s canal. Further dissection in this plane past Schwal-
be’s line creates the descemetic window, which should be
approximately 500 microns in length (Fig. 5). Aqueous may
be seen percolating through the TDW in most but not all cases
at this point. Both ostia of the canal are dilated using the
iTrack microcatheter (iTrack-250, iScience Interventional,
Menlo Park, CA), which is then inserted into one of the os-
tium. As the microcatheter is inserted into the canal, the lights
are dimmed to allow visualization of the illuminating optical
ﬁber beacon through sclera (Fig. 6). If resistance is encoun-
tered retract the microcatheter, insert it through the opposite
ostium and advance. After successful 360 cannulation of
Schlemm’s canal a 9-0 or 10-0 polypropylene suture (Prolene,
Ethicon, Switzerland) is tied to the tip of the microcatheter,
which is then retracted thus introducing the suture throughout
the circumference of the canal (to the authors’ knowledge, no
studies have compared 9-0 to 10-0 Prolene; however, it has
been reported that 10-0 is more effective at distending
Schlemm’s canal and lowering IOP when compared with 6-0
Prolene (Grieshaber et al., 2010c). While retracting the micro-
catheter ophthalmic viscosurgical device (OVD) is injected into
the canal at a rate of 0.5 lL/2 h or 1/8th turn of the OVD injec-
tor every 2 clock-hours. The suture is removed from the micro-
catheter and carefully tied to allow adequate tension on
Schlemm’s canal while avoiding inadvertent trabeculotomy.
Adequate suture tension is paramount to achieve proper
360 distension of Schlemm’s canal.
The deep scleral ﬂap is excised followed by water-tight clo-
sure of the superﬁcial ﬂap with interrupted 10-0 nylon sutures.
Alternatively, the superﬁcial ﬂap may be left unsutured if no
ﬂow is noted. Tenon’s capsule and conjunctiva are closed with
332 B.J. Harvey, M.A. Khaimi8-0 Vicryl at the limbus, and the surgery is concluded with
injection subconjunctival antibiotics and application of topical
antibiotic-steroid ointment.
3. Canaloplasty combined with cataract surgery
Combining cataract and glaucoma surgery is often necessary,
as glaucoma surgery can cause cataract progression (AGIS
Investigators, 2001). In addition, cataract surgery alone has
been shown to lower IOP anywhere from 1 to 5 mmHg (Shin-
gleton et al., 2006; Hayashi et al., 2001; Mathalone et al.,
2005). Furthermore, phacocanaloplasty shows a lower IOP
trend than canaloplasty alone (Lewis et al., 2011); therefore,
combining the two has gained popularity.
Cataract surgery may be combined with canaloplasty with
simple adjustments or steps added during the procedure. Phac-
oemulsiﬁcation ensues prior to canaloplasty using the surgeons
preferred techniques. A side port incision is made followed by
introduction of OVD into the anterior chamber. Size, shape
and relative location of clear corneal incisions may vary, but
keep in mind that both side port and clear corneal incisions
must be placed in a manner as to not intersect the corneal trac-
tion suture that will be necessary at the beginning of canalopl-
asty. When operating on either eye, both incisions may be
skewed inferotemporally to avoid such complications. Com-
plete and thorough removal of OVD is key to avoid postoper-
ative IOP spikes, which may be detrimental to glaucoma
patients. Finally, the clear corneal incision is sutured in order
to maintain anterior chamber stability during canaloplasty,
which is then performed using the technique previously de-
scribed above.4. Postoperative care
Postoperatively, patients are placed on a low-dose steroid and
a third or fourth generation ﬂuoroquinolone drop three-to-
four times per day. The steroid drop must be weaned quickly,
preferably within two weeks, as we have found a more pro-
nounced steroid response in patients undergoing canaloplasty.
This anecdotal data may be at least partially attributed to the
OAG patient population who are at higher risk for steroid re-
sponse (Kersey and Broadway, 2006); however, other factors
may be contributing to this phenomenon after the trabeculo-
canalicular outﬂow system alteration occurs via canaloplasty.
Relative incidence and etiology of steroid response post cana-
loplasty have yet to be fully investigated.
5. Discussion
The most comprehensive evaluation of canaloplasty was per-
formed by Lewis et al. (2011) in their 3-year international mul-
ticenter prospective study. Patients were included if they had
OAG and a baseline IOP of P16 mmHg and a historical
IOP of P21 mmHg. Angle-closure glaucoma (primary or sec-
ondary), uveitic glaucoma and angle recession glaucoma pa-
tients were excluded. Patients who underwent more than two
laser trabeculoplasties were also excluded. At three years, the
mean postoperative IOP for all eyes (n= 157) was decreased
from 23.8 ± 5.0 mmHg on 1.8 ± 0.9 medications to
15.2 ± 3.5 mmHg on 0.8 ± 0.9 medications demonstrating a36.1% IOP decrease from baseline. These patients were di-
vided into subsets for subsequent analysis. Overall, successful
tensioning suture placement occurred in 84.7% of patients
(n= 133). Successful suture placement within Schlemm’s ca-
nal after canaloplasty alone was performed in 103 eyes with
36-month data available for 89 eyes. Of this subset, there
was a 34% IOP decrease from baseline from 23.5 ± 4.5 mmHg
on 1.9 ± 0.8 medications to 15.5 ± 3.5 mmHg on 0.9 ± 0.9
medications at 36 months. Canaloplasty with successful suture
placement combined with phacoemulsiﬁcation was performed
in 30 eyes with 36-month data available for 27 eyes. Baseline
IOP decreased from 23.5 ± 5.2 mmHg on 1.5 ± 1.0 medica-
tions to 13.6 ± 3.6 mmHg on 0.3 ± 0.5 medications at
36 months postoperatively accounting for a 42.1% reduction.
There was a trend for lower IOP after phacocanaloplasty ver-
sus canaloplasty, but this difference was not signiﬁcant
(p= 0.95). Intraocular pressure in the low teens has been re-
ported in other studies as well following the combined proce-
dure (Bull et al., 2001; Shingleton et al., 2008). In all groups,
the IOP and medication use was signiﬁcantly decreased at all
time intervals compared to baseline (p< 0.001).
Lewis et al. (2009) further delineated response to canalopl-
asty based on degree of canal distension. Using high-resolution
anterior segment ultrasound biomicroscopy (UBM) analyzed
before, during and after surgery the investigators were able
to develop a grading system of suture tension on Schlemm’s
canal. Application of this scale allowed objective evaluation
of canal distension and its effect on postoperative IOP reduc-
tion in eyes that received canaloplasty alone. These eyes were
divided into discernable or no discernable distension with the
former showing a 31% IOP decrease and the latter showing
a 20% IOP decrease exemplifying a signiﬁcantly exaggerated
IOP-lowering response at 24 months in eyes with effective su-
ture tensioning on Schlemm’s canal (p= 0.018).
Another long-term study investigated the efﬁcacy of cano-
loplasty and phacocanaloplasty on European eyes with open-
angle glaucoma (Bull et al., 2001). One hundred and nine
eyes were included in the study with successful intracanalicu-
lar suture tensioning occurring in 98 eyes (89.9%), canalopl-
asty alone performed in 93 eyes (85.3%) and
phacocanaloplasty performed in 16 eyes (14.7%) with 3-year
follow-up data available for 96 eyes (88.1%). In the canalopl-
asty alone group the mean baseline IOP of 23.0 ± 4.3 mmHg
on an average 1.9 ± 0.7 medications was signiﬁcantly re-
duced to 15.1 ± 3.1 mmHg on 0.9 ± 0.9 medications while
the phacocanaloplasty group’s mean baseline IOP of
24.3 ± 6.0 mmHg on an average 1.5 ± 1.2 medications was
signiﬁcantly reduced to 13.8 ± 3.2 mmHg on 0.5 ± 0.7 med-
ications (p< 0.00001).
Grieshaber et al. (2011) published a series with similar re-
sults. Thirty-two white patients with open angles,
IOP > 21 mmHg, glaucomatous optic neuropathy and corre-
sponding visual ﬁeld defects who underwent canaloplasty were
included in this study. Patients were excluded if they received
previous ocular surgery or laser. Complete success (IOP reduc-
tion without medications) occurred in 93.8% with IOP 6 21,
84.4% with IOP 6 18, and 74.9% with IOP 6 16 12 months
postoperatively. Before canaloplasty, the mean IOP and num-
ber of medications were 27 ± 5.6 mmHg and 2.7 ± 0.5 medi-
cations, respectively. Eighteen months after canaloplasty the
mean IOP and number of medications were 13.1 ± 1.2 mmHg
and 0.1 ± 0.3 medications, respectively.
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canaloplasty appears to be effective in black and Asian popula-
tions as well. Grieshaber et al. (2010a) also published long-term
data with a mean follow-up of 30.6 ± 8.4 months on canalopl-
asty performed on black Africans, the majority of which (98%)
received canaloplasty as primary glaucoma treatment. In this
study, 60 consecutive POAG patients were selected to receive
canaloplasty. The mean preoperative IOP was
45.0 ± 12.1 mmHg. At 6, 12, 24 and 36 months postopera-
tively the mean IOP without medications was
15.4 ± 5.4 mmHg (n= 57), 15.4 ± 5.2 mmHg (n= 54), 16.3
± 4.2 mmHg (n= 51), and 13.3 ± 1.7 mmHg (n= 49),
respectively. Complete success deﬁned as IOP 6 21 mmHg
without medications was achieved in 77.5%, and qualiﬁed suc-
cess (IOP 6 21 mmHgwith or without medications) was seen in
81.6% of patients at 36 months. Ninety-ﬁve percent of patients
had no deterioration of Snellen visual acuity at 36 months.
A small case series of Japanese patients receiving canalopl-
asty or phacocanaloplasty is also present in the literature (Fuj-
ita et al., 2011). In this study 11 eyes of 9 Japanese patients
with POAG underwent canaloplasty (three eyes) or phacocan-
aloplasty (eight eyes). The mean preoperative IOP was
23.4 ± 5.5 mmHg on 2.8 ± 0.6 medications. At 1, 3, 6 and
12 months the mean IOP was 13.7 ± 2.8 mmHg,
12.8 ± 3.5 mmHg, 14.0 ± 4.4, and 15.0 ± 4.1, respectively.
The mean postoperative medications signiﬁcantly decreased
to 1.2 ± 0.8 (p< 0.01). A qualiﬁed success rate with and
IOP 6 21, 18 or 16 mmHg with or without medications at
12 months was achieved in 81.8, 54.5 and 54.5%, respectively.
6. Adverse events
When compared to trabeculectomy, canaloplasty offers a more
favorable side effect proﬁle; however, one must be aware of po-
tential complications encountered during or after this proce-
dure. Intraoperative complications include inability to
cannulate Schlemm’s canal, Descemet membrane detachment
and improper microcatheter passage (Lewis et al., 2011; Bull
et al., 2001; Shingleton et al., 2008; Lewis et al., 2009; Grieshab-
er et al., 2011; Grieshaber et al., 2010a; Fujita et al., 2011). Suc-
cessful 360 cannulation of Schlemm’s canal with
intracanalicular suture placement was see in 84.7% of eyes in
Lewis’s 3-year study and 74–89.9% in other studies (Lewis
et al., 2011; Bull et al., 2001; Shingleton et al., 2008). Unsuccess-
ful 360 catheterization was usually attributed to early surgicalFigure 7 Descemet membrane detachment with entrapped
blood.inexperience or anatomical obstacles (Lewis et al., 2011; Shin-
gleton et al., 2008). All but one eye had successful cannulation
and suturing of SC in Grieshaber’s studies (Grieshaber et al.,
2011; Grieshaber et al., 2010a). No cannulation issues were re-
ported in Fujita’s case series (Lewis et al., 2009). Descemet
membrane detachment rate was uncommon, ranging from
1.6% to 9.1% (Lewis et al., 2011; Bull et al., 2001; Shingleton
et al., 2008; Lewis et al., 2009; Grieshaber et al., 2011; Gries-
haber et al., 2010a; Fujita et al., 2011) (Fig. 7). One case report
described bilateral descemet membrane detachment in one pa-
tient who underwent consecutive canaloplasty in each eye
(Palmiero et al., 2010), and another described an intracorneal
hematoma following a proposed intraoperative descemet mem-
brane detachment (Gismondi and Brusini, 2011). In rare set-
tings, the microcatheter could exit SC and violate
surrounding structures. This occurred in two patients (3.3%)
of Grieshaber’s black Africans receiving canaloplasty. The
microcatheter entered the anterior chamber in one patient
and the suprachoroidal space in another. In both instances
the microcatheter was retracted and successful cannulation en-
sued. Passage of the microcatheter into the suprachoroidal
space created a presumed ‘microcyclodialysis’ with subsequent
hypotony that spontaneously resolved. Breaking through the
TM into the anterior chamber may have introduced excess
OVD with a resultant hypertensive phase, which was success-
fully treated with a short course of oral acetazolamide (Gries-
haber et al., 2010a). Intraoperative trans-TM suture extrusion
occurred in one eye (0.8%) in Lewis et al. (2011) study.
Hyphema or microhyphema (deﬁned differently by differ-
ent authors) were the most common post canaloplasty com-
plications with a wide range of reported events depending on
qualifying parameters. Collectively, hyphemas and micro-
hyphemas ranged from 6.1% to 70% of eyes. All events were
transient and resolved without sequela with most resolving
by one week and all resolving by one month in every study
(Lewis et al., 2011; Bull et al., 2001; Shingleton et al., 2008;
Lewis et al., 2009; Grieshaber et al., 2011; Grieshaber et al.,
2010a; Fujita et al., 2011). Another common side effect noted
in Lewis’s and Bull’s 3-year studies was cataract formation
with 12.7% and 19.1% developing visually signiﬁcant cata-
racts, respectively (Lewis et al., 2011; Bull et al., 2001). Con-
versely, Grieshaber’s 3-year study demonstrated only a
temporary decline in VA, which returned to baseline in
95% of patients (Grieshaber et al., 2010a). Some eyes expe-
rienced an unexpected increase in pressure. Intraocular pres-
sure elevation P30 mmHg occurred in 1.6–18.2% of eyes,
which was thought by some authors to be secondary to re-
tained viscoelastic in the anterior chamber. Persistent eleva-
tion in IOP requiring laser goniopuncture was necessary in
8.3–18.8% in some studies; however, in other reports no eyes
required laser goniopuncture. Other postoperative complica-
tions reported in the literature include suture ‘cheese-wiring’
through the TM (up to 9.1%), wound hemorrhage (up to
2.5%) and hypotony (up to 0.6%) Lewis et al., 2011; Bull
et al., 2001; Shingleton et al., 2008; Lewis et al., 2009; Gries-
haber et al., 2011; Grieshaber et al., 2010a; Fujita et al.,
2011. Bleb formation occurred in only 2.5% of Lewis’s pa-
tients and none of Grieshaber’s patients at 36 months (Lewis
et al., 2011; Grieshaber et al., 2010a). Of note, no choroidal
detachment, suprachoroidal hemorrhage, blebitis or bleb-
associated endophthalmitis has been reported in the literature
to date.
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Contraindications for canaloplasty include patients with
chronic angle closure, narrow angles, angle recession, neovas-
cular glaucoma and in eyes that have undergone previous glau-
coma procedures that preclude adequate cannulation of
Schlemm’s canal (Godfrey et al., 2009). Chronic angle closure
causes increased intraocular pressure by obstructing the tra-
becular meshwork with the peripheral iris with subsequent
development of peripheral anterior synechiae (PAS). Such
obstruction is upstream from Schlemm’s canal; therefore, can-
aloplasty may be ineffective. Similarly neovascular glaucoma
covers the TM with a neovascular membrane that eventually
contracts leading to the development of PAS and secondary
angle closure. Uveitic glaucoma may develop secondary to
obstruction of the TM with inﬂammatory debris or secondary
to inﬂammation-induced PAS formation. Procedures that may
prevent adequate cannulation of Schlemm’s canal include (but
are not limited to) trabeculectomy, trabeculotomy, goniotomy,
argon laser trabeculoplasty (ALT), trabectome (NeoMedix
Inc., Tustin, California, USA), iStent Trabecular Micro-By-
pass (Glaukos Corp., Laguna Hills, California, USA), and
Eyepass Glaucoma Implant (GMP Companies Inc., Fort Lau-
derdale, Florida, USA). Trabeculotomy, either ab externo or
ab interno, and goniotomy violate the inner wall of Schlemm’s
canal; therefore, adequate tension may not be distributed to
the canal. Similarly, the trabectome, which uses an electrocau-
tery tip to remove portions of the TM and the inner wall of
Schlemm’s canal removes the essential anatomy required in
canaloplasty. ALT may cause extensive scarring which can ob-
struct circumferential cannulation of the canal (Godfrey et al.,
2009; Mosaed et al., 2009). The Micro-Bypass implants them-
selves may block microcatheter advancement. Additionally,
success of canaloplasty may be limited if aqueous outﬂow
channels distal to the canal are collapsed or scarred. Some
authors have described intraoperative injection of ﬂuorescein
into Schlemm’s canal via the microcatheter enabling in vivo
visualization of the aqueous outﬂow system (channelography),
which may elucidate the outﬂow capacity and predict how a
patient may respond to canaloplasty (Grieshaber et al.,
2009). These implications have yet to be validated.
8. Ideal pt selection
Ideal patient selection is key when considering canaloplasty.
Patients with mild-to-moderate open-angle glaucoma with an
IOP goal in the low-to-mid teens would beneﬁt greatly from
canaloplasty. In addition, advanced glaucoma may be treated
with canaloplasty in patients who are not suitable for trabecu-
lectomy. For example, those who cannot adhere to the rigor-
ous postoperative care required after trabeculectomy may
undergo canaloplasty instead as the follow-up appointments
and postoperative drops are less frequent. In eyes with thin
conjunctiva that may be at higher risk for bleb leaks after tra-
beculectomy with mitomycin C, canaloplasty may be the pre-
ferred procedure (Borisuth et al., 1999). Conversely, young
black patients with more robust scar formation should under-
go canaloplasty if bleb failure secondary to scarring is of con-
cern (Broadway et al., 1994; The Advanced Glaucoma
Intervention Study, 2001; Ederer et al., 2004). One may con-
sider combining phacoemulsiﬁcation with canaloplasty if avisually signiﬁcant or early visually signiﬁcant cataract surgery
is anticipated in the near future or if a phacomorphic glau-
coma component exists. Phacocanaloplsty has also been
shown to lower IOP more than canaloplasty alone (Lewis
et al., 2011). Due to the low side effect proﬁle and efﬁcacy of
canaloplasty, it may be strongly considered in monocular pa-
tients with OAG as well thereby sparing the patient the lifelong
bleb-related risks. Far less hypotony is seen after canaloplasty
as opposed to trabeculectomy (0.6% versus 42.3%), so the for-
mer should be considered in young myopic individuals who are
at an increased risk for hypotony maculopathy (Fannin et al.,
2003).9. Conclusion
Canaloplasty has been shown in the literature to be a viable
alternative to more traditional incisional glaucoma surgery.
Viscodilating Schlemm’s canal using a ﬂexible, beacon-tipped
microcatheter with subsequent suture tensioning is designed
to be a blebless procedure that requires no antiﬁbrotic agents
and has been suggested to restore the natural outﬂow system
of the eye (Khaimi, 2009). Canaloplasty targets the pathologic
site of maximal aqueous outﬂow resistance in open-angle glau-
coma theoretically by stretching Schlemm’s canal and adjacent
juxtacanalicular outﬂow system, and a pilocarpine-like effect
on the TM may occur as well (Lewis et al., 2011; Grieshaber
et al., 2010a). The effect of suture tensioning may actually alter
the anatomical structure of the TM to favor aqueous outﬂow
over time. This and/or delayed re-opening of distal collector
channels has been proposed to offer mild, late IOP reduction
remotely after surgery (Grieshaber et al., 2010a). Canaloplasty
has repeatedly been shown to be safe and effective at signiﬁ-
cantly lowering IOP and medication dependence in different
patient populations with OAG. Whites, blacks and select
Asian populations respond similarly to canaloplasty making
this procedure favorable for many races despite the more ro-
bust scar tissue formation seen in blacks or the narrower angle
anatomy seen in Asians. Furthermore, Cox regression analyses
in select studies have identiﬁed no preoperative predictors of
IOP after surgery including preoperative IOP, gender and
age (Lewis et al., 2011; Grieshaber et al., 2011; Grieshaber
et al., 2010a; Fujita et al., 2011). In fact, stark differences in
preoperative IOP of patients receiving canaloplasty alone in
Lewis’s and Grieshaber’s 3-year studies still yielded similar
mean postoperative IOP. The former had a mean preoperative
IOP of 23.5 ± 4.5 mmHg while the latter had a mean preoper-
ative IOP of 45.0 ± 12.1 mmHg. Despite this disparity, the
resultant mean postoperative IOPs were similar in each study
(15.5 ± 3.5 mmHg and 13.3 ± 1.7 mmHg). This may repre-
sent the inability of canaloplasty to overcome episcleral venous
pressure thus limiting IOP reduction below 12 mmHg (Gries-
haber et al., 2010a).
We believe that canaloplasty offers a more favorable safety
proﬁle when compared with trabeculectomy. Hyphema or
microhyphema were by far the most common complications
reported in the major canaloplasty literature to date. Some
authors posit hyphemas are signs of surgical success after can-
aloplasty conveying re-establishment of a patent natural out-
ﬂow system as red blood cells driven by episcleral venous
pressure egress out of the canal, through the TM and into
the anterior chamber (Grieshaber et al., 2010a,b). One but
A review of canaloplasty 335not all studies had an increase in cataract formation 3 years
after canaloplasty. Lewis et al. listed cataract formation as
the most common late postoperative complication 3 years after
canaloplasty occurring in 12.7%; however, this was not the
case in Grieshaber’s 3 year follow-up on black Africans post
canaloplasty. Perhaps the increased cataract formation in Le-
wis’s study can be attributed to age-related changes rather than
changes related to the surgery, as Lewis’s patients were on
average older than Grieshaber’s black African patients
(67 ± 11.6 years versus 49.8 ± 15.7 years) (Lewis et al.,
2011; Grieshaber et al., 2010a). Cataract progression after can-
aloplasty is still less frequent than after trabeculectomy, which
has been reported to increase the risk of cataract formation by
47% (AGIS Investigators, 2001). Hypotony after canaloplasty
was reported in 0.6% of a predominantly white population
(91.7%) (Lewis et al., 2011). This percentage is far more favor-
able than the incidence of hypotony in whites after trabeculec-
tomy, which has been reported to be as high as 13.8%
(Borisuth et al., 1999). Probably the most signiﬁcant advances
canaloplasty offers are the lack of choroidal detachments,
suprachoroidal hemorrhage, blebitis or bleb-related endoph-
thalmitis observed in any eyes treated with canaloplasty or
phacocanaloplasty (Lewis et al., 2011; Bull et al., 2001; Shin-
gleton et al., 2008; Lewis et al., 2009; Grieshaber et al., 2011;
Grieshaber et al., 2010a; Fujita et al., 2011; Khaimi, 2009).
Canaloplasty is designed to be a blebless procedure, and in
fact, only 2.5% of patients developed blebs (Lewis et al.,
2011). However, no bleb-related complications resulted. The
incidence of bleb-associated endophthalmitis has been re-
ported in 0.2–9.6% of patients after trabeculectomy, which in-
creases to 2.5% per patient-year with the addition of
mitomycin C (Greenﬁeld et al., 1996; Prasad and Latina,
2007).
In summary, canaloplasty has become an appealing alter-
native to traditional incisional glaucoma therapies. It is less
invasive, blebless, no mitomycin C is necessary. While cana-
loplasty is effective in lowering IOP and medication depen-
dence, it still has its limitations. It may be contraindicated
in patients with chronic angle closure, narrow angles, angle
recession, neovascular glaucoma and in eyes that have under-
gone previous glaucoma procedures that preclude adequate
canulation of Schlemm’s canal. If pressure lowering below
mid-to-low teens is desired then a trabeculectomy with anti-
ﬁbrotics or glaucoma drainage implant may be preferred over
canaloplasty, which may not be the best option in patients
with advanced glaucoma in need of very low IOP. There is
a learning curve for successful catheterization of Schlemm’s
canal, and certain anatomical variations may prohibit suc-
cessful catheterization such as the microcatheter tip entering
a large collector channel or meeting unknown resistance
(Lewis et al., 2011). The pressure-lowering effects and the rel-
atively low side effect proﬁle of canaloplasty appear sound,
but this must be weighted against traditional measures.
Mosaed et al. (2009) published a literature review comparing
trabeculectomy, glaucoma drainage devices, trabectome and
canaloplasty claiming trabeculectomy is ‘the most effective
IOP-lowering procedure to date’. There was, however, no
standardization amongst the different studies analyzed nor
were any of the procedures directly compared. Canaloplasty
has only been directly compared to viscocanalostomy in a ret-
rospective case series, which determined the former to be
more efﬁcacious than the latter (Koerber, 2011). Recentlythe American Academy of Ophthalmology commissioned
the Ophthalmic Technology Assessment Committee Glau-
coma Panel to review the available literature on the efﬁcacy
of novel glaucoma procedures including canaloplasty. The
panel concluded that with the current data it is impossible
to state canaloplasty or other novel glaucoma procedures
are superior, inferior or equal to traditional glaucoma surger-
ies or to each other (Francis et al., 2011). Ultimately, ran-
domized clinical trials comparing canaloplasty to traditional
and other novel glaucoma procedures with standardized def-
initions of success and failure, inclusion and exclusion criteria
and follow-up period are required to determine its efﬁcacy.
Future studies are also needed to explore the long-term ef-
fects of canaloplasty on IOP and the remote side effects of
this procedure; however, currently canaloplasty appears to
be a valuable tool in the armamentarium of glaucoma
procedures.Conﬂict of interest statement
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